US9078923 — Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
Method of Use · Assigned to Glenmark Pharmaceuticals Ltd · Expires 2034-09-04 · 8y remaining
What this patent protects
This patent protects a stable fixed dose pharmaceutical composition for nasal administration that contains mometasone or its salt and olopatadine or its salt.
USPTO Abstract
The present invention relates to a stable fixed dose aqueous pharmaceutical composition (e.g., contained in a container) for nasal administration to a human, comprising mometasone or its salt, olopatadine or its salt. The composition may further include a hydrocolloid. The invention also relates to a process for preparing the pharmaceutical composition, and the use of the pharmaceutical composition in the treatment of rhinitis in a subject.
Drugs covered by this patent
- Elocon (MOMETASONE FUROATE) · Merck & Co.
FDA Patent Use Codes
When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.
| Code | Description | Drug |
|---|---|---|
U-3297 |
— | Elocon |
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.